Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 40, Issue 4, 1997, Pages 775-778

  Lafferty, Thomas E ^a   Smith, J Bruce ^a   Schuster, Stephen J ^a   DeHoratius, Raphael J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN;

ADULT; ANTIBODY TITER; ARTICLE; BLEEDING; CASE REPORT; FEMALE; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FACTOR VIII; FEMALE; HEMORRHAGIC DISORDERS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030915347     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400426     Document Type: Article

References (12)

1. Feinstein DI: Acquired inhibitors against factor VIII and other clotting proteins. In, Hemostasis and Thrombosis. Second edition. Edited by RW Colman, J Hirsh, MJ Marder, E Salzman. Philadelphia, JW Lippincott, 1987
2. Lusher JM: Factor VIII inhibitors: etiology, characterization, natural history, and management. Ann N Y Acad Sci 509:89-102, 1987
3. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Consensus statement - recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 273:1865-1870, 1995
4. Margolius A Jr, Jackson DP, Ratnoff OD: Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 40:145-202, 1961
5. Gobbi F, Stefanini M: Circulating anti-AHG anticoagulant in a patient with lupus erythematosus disseminatus: effect of a cephalin complex in vivo. Acta Haematol 28:155-162, 1962
6. Robboy SJ, Lewis EJ, Schur PH, Colman RW: Circulating anticoagulants to factor VIII: immunochemical studies and clinical responses to factor VIII concentrates. Am J Med 49:742-752, 1970
7. Green D, Lechner K: A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 45:200-203, 1981
8. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE: Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2:765-768, 1984
9. Zimmermann R, Kommerell B, Harenberg J, Eich W, Rother K, Schimpf KL: Intravenous IgG for patients with spontaneous inhibitor to factor VIII. Lancet 1:273-274, 1985
10. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM: A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin. Blood 86:797-804, 1995
11. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121:259-262, 1994
12. Duhem C, Dicato MA, Ries F: Side-effects of intravenous immune globulins. Clin Exp Immunol 97 (suppl 1):79-83, 1994